LUGPA 2024 Enduring CME Program: Emerging Technologies to Advance Urologic Care in 2025-LUGPA 2024 CME Program Part 3

Video Transcription

Video Summary

The video features a discussion among experts in urology, including Dr. Kevin McVary from Loyola University, Tim McClure from Cornell, and Kevin Zorn from Canada, focusing on benign prostatic hyperplasia (BPH) and related treatments. Dr. McVary, an authority in the field, discusses various patient scenarios, employing different treatment methods. First, they explore the management of a 62-year-old man with lower urinary tract symptoms (LUTS) using diagnostic tools and evaluating whether to proceed with medical or surgical intervention. Tim McClure emphasizes thorough evaluations, including prostate MRIs and urodynamic assessments.<br /><br />The panel also discusses the management of prostatic conditions in anticoagulated patients, options for which include Green Light Laser therapy or partial procedures like Resume. They examine updated studies on prostate artery embolization (PAE) which shows potential for symptom relief, though with caveats on study interpretation and reproducibility.<br /><br />They briefly mention new technology like MRI improvements and artificial intelligence in diagnostics, with an emphasis on balancing modern techniques with cost and patient outcomes. A segment on the limitations and considerations of hypofractionated radiation therapies wraps up the BPH topic.<br /><br />Subsequent talks by Dr. Eggener examine cutting-edge therapies in prostate cancer, stressing the importance of integrating new technologies like genomic testing and liquid biopsies while being wary of overuse and ensuring patient benefit guides decisions.

Keywords

urology

benign prostatic hyperplasia

BPH treatments

lower urinary tract symptoms

LUTS

prostate artery embolization

Green Light Laser therapy

artificial intelligence diagnostics

prostate cancer therapies

genomic testing